Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RGX-202
GENETIC
2 trials
Sponsors
REGENXBIO Inc.
Conditions
Duchenne Muscular Dystrophy
Phase 2
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
Active, not recruiting
NCT05693142
REGENXBIO Inc.
Duchenne Muscular Dystrophy
Start: 2023-01-04
End: 2028-06-01
Target: 65
Updated: 2026-07-21
Unknown Phase
Expanded Access to RGX-202
NCT07652606
REGENXBIO Inc.
Updated: 2026-06-17